LVTX — LAVA Therapeutics NV Share News
0.000.00%
Last trade - 00:00- $45.77m
- -$3.89m
- $11.98m
Brief: LAVA Therapeutics Q2 basic EPS USD -0.48
Brief: Lava Therapeutics Provides Updates On Clinical Programs, Extends Cash Runway
Brief: Lava Therapeutics Reports Q1 2023 Results
U.S. STOCKS ON THE MOVE-Ford Motor, Theratechnologies, 3D Systems
Lava gains after Janssen selects cancer therapy candidate for partnership
Brief: LAVA Therapeutics Announces Selection By Janssen Of Lead Gamma-Delta T-Cell Engager Bispecific Antibody
Lava Therapeutics Nv Expected To Post A Loss Of 51 Cents A Share: Earnings Preview
Lava Therapeutics rises on smaller loss than expected in Q4
Lava Therapeutics Nv Reports Results For The Quarter Ended In December: Earnings Summary
Brief: Lava Therapeutics Reports Fourth Quarter And Year-End 2022 Results
Lava Therapeutics Nv Expected To Post A Loss Of 62 Cents A Share: Earnings Preview
Brief: Lava Therapeutics Announces Appointment Of Christy J. Oliger To Its Board Of Directors
Brief: Lava Therapeutics Announces Initial Data From The Ongoing Phase 1/2A Clinical Trial Of Lava-1207 In Therapy Refractory Mcrpc At The 2023 Asco Gu Symposium
Brief: LAVA Therapeutics Provides Business Update, Reports Third Quarter Financial Results
Lava Therapeutics Nv Reports Results For The Quarter Ended In September: Earnings Summary
Lava Therapeutics Nv Expected To Post A Loss Of 14 Cents A Share: Earnings Preview
Brief: Lava Therapeutics To Present Updated Data From The Phase 1/2A Clinical Trial Of Lava-051 At The 64Th American Society Of Hematology (Ash) Annual Meeting And Exposition
Brief: Lava Therapeutics Announces Appointment Of Fred M. Powell As Chief Financial Officer
Seagen's recent licensing deals signal M&A unlikely this year - William Blair